Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation

Ann‐Christin Pecher(Center for Rheumatology), Jörg Henes(University of Tübingen), Luca Hensen(University Children's Hospital Tübingen), V Richter(STZ eyetrial), Markus C. Kowarik(Hertie Institute for Clinical Brain Research), Claudia Lengerke(STZ eyetrial), Rebekka Schairer-Marquardt(STZ eyetrial), Wolfgang Bethge(University of Tübingen)

Annals of the Rheumatic Diseases

April 30, 2025

10.1016/j.ard.2025.03.018

Cited by 17

Related Papers

Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation

|Blood|2010|430

Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies

|JAMA|2011|320

Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)

|Journal of Clinical Oncology|2017|248

CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome

|JAMA|2023|234

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

|Journal of Clinical Oncology|2013|212